An Observational Study of Avastin (Bevacizumab) and Interferon Alpha 2a in Patients With Metastatic Renal Cell Cancer (VERA)

Hoffmann-La Roche40 enrolled

Overview

This prospective observational study will evaluate the efficacy and safety of Avastin (bevacizumab) in combination with interferon alpha 2a in patients with previously untreated metastatic renal cell cancer. Data will be collected from each patient for up to 4 years.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Renal Cell Cancer

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Adult patients, \>/= 18 years of age * Histologically confirmed metastatic renal cell cancer, clear cell type * Eligible for treatment with Avastin and interferon alpha 2a according to local prescribing information Exclusion Criteria: * Contraindications for Avastin or interferon alpha 2a treatment according to local Summary of Product Characteristics * Known hypersensitivity to Avastin and/or interferon alpha 2a or any of its excipients

Locations (1)

Unnamed facility

Cluj-Napoca, Romania

Outcomes

Primary Outcomes

Progression-free survival

Time frame: approximately 4 years

Secondary Outcomes

Overall survival

Time frame: approximately 4 years

Response rate

Time frame: approximately 4 years

Safety: Incidence of adverse events

Time frame: approximately 4 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.